Thionicotinamide → N-Ethyl-N'-[7-(3-pyridyl)-4,5-dihydro[1,3]thiazolo[4',5': 3,4]benzo[d][1,3]thiazol-2-yl]urea

HRID 9151

Reaction equation

Br[CH:2]1[CH2:16][CH2:15][C:5]2[N:6]=[C:7]([NH:9][C:10]([NH:12][CH2:13][CH3:14])=[O:11])[S:8][C:4]=2[C:3]1=O.[C:18]([NH2:26])(=[S:25])[C:19]1[CH:24]=[CH:23][CH:22]=[N:21][CH:20]=1>C(O)CC>[CH2:13]([NH:12][C:10]([NH:9][C:7]1[S:8][C:4]2[C:3]3[N:26]=[C:18]([C:19]4[CH:20]=[N:21][CH:22]=[CH:23][CH:24]=4)[S:25][C:2]=3[CH2:16][CH2:15][C:5]=2[N:6]=1)=[O:11])[CH3:14]

Participants

Conditions

Temperature: 105 °C

Procedure

A suspension of N-(6-bromo-7-oxo-4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)-N′-ethylurea (25 mg, 0.079 mmol) and thionicotinamide (11 mg, 0.079 mmol) in n-propanol (0.4 mL) was heated to about 105° C. for about 16 hrs. The reaction mixture was concentrated in vacuo and the residual crude material was purified by preparative HPLC. 10 mg (36%) pure product was isolated.

Workup

concentrationThe reaction mixture was concentrated in vacuo
customthe residual crude material was purified by preparative HPLC

Sources & evidence

ORD record: ord-a17813f0e3914b2492892bf738b5e7ad
Source dataset: uspto-grants-2006_08
DOI: 10.6084/m9.figshare.5104873.v1
Patent number: US07091227B2

Linked notes

Loading…